Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 15 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Romiopoulos, Iordanis [Clear All Filters]
Active Helicobacter pylori infection on colorectal mucosa--adenomatous polyp--adenocarcinoma sequence..
Eur J Gastroenterol Hepatol. 26(2), 243-4.
(2014). Acute Liver Failure: From Textbook to Emergency Room and Intensive Care Unit With Concomitant Established and Modern Novel Therapies..
J Clin Gastroenterol. 53(2), 89-101.
(2019).
(2017).
(2014).
Helicobacter pylori and colorectal cancer risk--letter..
Cancer Epidemiol Biomarkers Prev. 23(2), 365.
(2014). Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?.
Int J Cardiol. 233, 92.
(2017). Helicobacter pylori infection and colorectal carcinoma: pathologic aspects..
J Gastrointest Oncol. 3(4), 377-9.
(2012). Helicobacter pylori might contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors..
Hepatology. 60(4), 1450-1.
(2014). Helicobacter pylori on portal hypertension-related hepatic encephalopathy..
Immunopharmacol Immunotoxicol. 39(2), 105-106.
(2017). Is Helicobacter pylori the usual suspect behind gastroesophageal reflux disease and dacryostenosis?.
Med Hypotheses. 81(1), 147.
(2013). Helicobacter pylori-related metabolic syndrome might justify earlier colorectal cancer screening..
Gastrointest Endosc. 80(1), 188-9.
(2014). Impact of Helicobacter pylori Infection on colon oncogenesis..
Am J Gastroenterol. 108(4), 625-6.
(2013). Impact of reactive oxygen species generation on Helicobacter pylori-related extragastric diseases: a hypothesis..
Free Radic Res. 51(1), 73-79.
(2017). A Rare Case of Disseminated Pyogenic Gonococcal Infection in an Immunocompetent Woman..
Case Rep Infect Dis. 2016, 9629761.
(2016). Serum visfatin in nonalcoholic fatty liver disease..
Ann Hepatol. 13(1), 150-1.
(2013).